Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results…
Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing…
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain movement, and investor sentiment as oil and freight costs rise. The…
The stock market is now looking at the US-Israel-Iran conflict through a sharper pharma lens. This is no longer only a war story, an…
